Analysis of p53 Protein Expression in Hepatocellular Carcinoma

2016 ◽  
Vol 25 (3) ◽  
pp. 345-349 ◽  
Author(s):  
Florin Graur ◽  
Luminita Furcea ◽  
Emil Mois ◽  
Andrei Biliuta ◽  
Aliz-Timea Rozs ◽  
...  

Background & Aims: Hepatocellular carcinoma (HCC) has a growing incidence and studies regarding the risk factors or pathogenesis for this type of carcinoma benefit special interest. This study evaluates the correlations between p53 protein expression and clinical and laboratory factors in patients withHCC. Methods: The study group included 76 patients diagnosed with HCC, either by biopsy or after surgical resection (with curative intent). Immunohistochemistry for p53 protein assessment was performed in all patients. Correlations between the protein 53 expression and age, tumour size, viral infection, liver cirrhosis were performed using the chi-square test (Pearson‘s chi-square) together with the contingency coefficient Kendall‘s coefficient in the tau-b form. Results: In the study group, 51 patients were male (67%) and 25 female (33%). Cirrhosis due to hepatitis virus B or C infection (in a proportion of 63% of the study group) was not significantly associated with the presence of HCC. Altered expression of p53 protein was observed in 69 patients (91%). The relationship between p53 protein expression and patient sex (p=0.067), age (p=0.531), tumour size (p=0.270), presence of hepatitis B and C viral infections (p=0.7), and of liver cirrhosis (p=0.511) was not statistically significant. Conclusion: The p53 protein expression was not significantly associated with the demographic characteristics of the patients, tumour size, presence of viral B and C infections or liver cirrhosis. Abbreviations: HBV: hepatitis B virus; HCV: hepatitis C virus; HCC: hepatocellular carcinoma; TP53: tumour protein p53; MDR: multi-drug resistance gene.

1997 ◽  
Vol 121 (2) ◽  
pp. 203-210 ◽  
Author(s):  
Guozhong Qin ◽  
Jianjia Su ◽  
Yaoyu Ning ◽  
Xiaoxian Duan ◽  
Dan Luo ◽  
...  

2004 ◽  
Vol 11 (6) ◽  
pp. 502-510 ◽  
Author(s):  
M. Anzola ◽  
A. Saiz ◽  
N. Cuevas ◽  
M. Lopez-Martinez ◽  
M. A. Martinez de Pancorbo ◽  
...  

1997 ◽  
Vol 136 (4) ◽  
pp. 382-387 ◽  
Author(s):  
Victoria L Green ◽  
Michael C White ◽  
Leslie J Hipkin ◽  
Richard V Jeffreys ◽  
Patrick M Foy ◽  
...  

Abstract Human anterior pituitary adenomas proliferate and express the p53 tumour suppressor gene protein, but it is not known if apoptosis (programmed cell death) occurs. Therefore, the detection of apoptosis was undertaken in tumorous human anterior pituitary tissue and compared with p53 protein expression, tumour type and tumour size. Apoptosis (detected by the in situ end labelling technique) and p53 suppressor gene protein (detected by DO. 1-antibody immunocytochemistry) were determined in formalin-fixed and paraffin-embedded tissue from 37 human pituitary adenomas (2 macroprolactinomas, 9 somatotrophinomas and 26 non-functioning adenomas). Two normal anterior pituitaries were also included in this study. Pre-operative tumour size was scored 1 to 4 from magnetic resonance imaging radiology. Apoptosis was found in 7 of 29 tumours (24%), 11% of somatotrophinomas and 33% of non-functioning adenomas, although this difference was not significant. The p53 tumour suppressor protein was found in 7 of 31 tumours (23%), 33% of somatotrophinomas and 19% of nonfunctioning adenomas. Apoptosis and p53 protein expression were not found in normal anterior pituitary. In conclusion, apoptosis occurs in human anterior pituitary adenomas, but no significant association was found between apoptosis and p53 protein expression, tumour type or tumour size. European Journal of Endocrinology 136 382–387


2020 ◽  
Author(s):  
S Ben Slama ◽  
D Bacha ◽  
A Ben Amor ◽  
A Halouani ◽  
A Lahmar

1995 ◽  
Vol 24 (1) ◽  
pp. 18-22 ◽  
Author(s):  
J. A. Regezi ◽  
R. J. Zarbo ◽  
E. Regev ◽  
S. Pisanty ◽  
S. Silverman ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document